Eli Lilly and Company (LLY)

Eli Lilly's stock has experienced significant positive momentum in the past six months. Strong Q1 2026 earnings, driven by its GLP-1 portfolio, led to a stock jump. Continued strong demand for Mounjaro and Zepbound has been a major driver of revenue growth. Positive news on oral GLP-1 (Foundayo) and Retatrutide has strengthened Lilly's position in obesity drugs. The FDA's proposal to curb mass compounding of Lilly's weight-loss drugs is seen as a meaningful tailwind. The company raised its full-year profit and revenue forecasts. In November 2025, the company reached a $1 trillion market capitalization.

Demand for Eli Lilly's pharmaceutical products can exhibit seasonality, driven by the fluctuating prevalence of certain illnesses throughout the year. Winter typically sees increased demand for cold and flu remedies, while spring and summer often bring a surge in demand for allergy medications and treatments for skin infections. Public health campaigns can also lead to significant fluctuations in demand. Pharmaceutical companies like Eli Lilly must monitor these seasonal disease patterns to adjust their manufacturing, marketing, and inventory management practices accordingly.

Eli Lilly & Co. is a global pharmaceutical company focused on discovering, developing, manufacturing, and selling pharmaceutical products across various therapeutic areas, including diabetes, obesity, oncology, immunology, and neuroscience. Key products include Tirzepatide (Mounjaro and Zepbound) for diabetes, weight loss and sleep apnea, Abemaciclib (Verzenio) for breast cancer, Dulaglutide (Trulicity) for diabetes, Ixekizumab (Taltz) for autoimmune diseases, Empagliflozin (Jardiance) for diabetes, Insulin lispro (Humalog) and Insulin (Humulin) for high blood glucose, Ramucirumab (Cyramza) for cancer treatment, Baricitinib (Olumiant) for rheumatoid arthritis and COVID-19, and Galcanezumab (Emgality) for migraine prevention. The company is also researching drugs in the obesity, diabetes, Alzheimer's, and autoimmune areas.

Eli Lilly has a substantial global presence with offices in 18 countries and products sold in approximately 125 countries, operating an extensive network of 402 subsidiaries across 57 countries. The United States is its largest revenue-generating region, followed by Europe, Japan, and China. Eli Lilly also has significant R&D and manufacturing sites in Europe and is expanding its manufacturing capabilities in regions like the US, Europe (Netherlands), and India.

Eli Lilly maintains a long-standing reputation in pharmaceutical research, supported by its ability to develop, manufacture, and commercialize medicines at scale within global healthcare. The company's current momentum reflects a strong connection between innovation, demand, and healthcare system needs. Eli Lilly's 2022 Nature Benchmark performance was modest, indicating potential for improvement in areas like social inclusion and community impact, but demonstrated strong practices in ecosystems and biodiversity. A notable event impacting its reputation positively was the announcement in March 2023 of a $35 cap on the price of monthly insulin.

Eli Lilly & Co. has a broad ownership structure dominated by institutional investors, with 4412 institutional owners and shareholders holding a total of 873,602,077 shares. The largest shareholder is Lilly Endowment Inc., controlling over 10% of the stock, followed by Vanguard Group Inc., BlackRock, Inc., and others. Insider and family stakes are small but historically symbolic.